BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research Annual Meeting 2022
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq
BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study
BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences
BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board
